Abstract
There is a striking congruence between the inhibitory effects of three synthetic entities on ADP-induced (i) human blood platelet aggregation and (ii) platelet factor 3 availability as evidenced by prolonged 'Stypven time'. The pronounced parallel between each compound's potency in inhibiting aggregation (e.g. IA 48.9 +/- 1.3, S.E., %; n = 16) and in impeding platelet factor 3 availability (e.g. IPF-3av 42.3 +/- 2.5, S.E., %; n = 12), determined concurrently in platelet-rich plasma of four different donors, further substantiates that the antiplatelet activity of our carbamoylpiperidine and nipecotoylpiperazine congeners is exerted through their interaction with anionic phospholipids.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenosine Diphosphate / physiology*
-
Adult
-
Animals
-
Blood Coagulation Factors / metabolism*
-
Humans
-
Male
-
Nipecotic Acids / metabolism
-
Nipecotic Acids / pharmacology*
-
Phosphatidylinositols / metabolism
-
Phosphatidylserines / metabolism
-
Piperazines*
-
Platelet Aggregation / drug effects*
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Factor 3 / metabolism*
Substances
-
Blood Coagulation Factors
-
Nipecotic Acids
-
Phosphatidylinositols
-
Phosphatidylserines
-
Piperazines
-
Platelet Aggregation Inhibitors
-
alpha, alpha'-bis(3-(N,N-diethylcarbamoyl)piperidino)-4-xylene
-
Platelet Factor 3
-
Adenosine Diphosphate
-
1,10-bis(3-(N,N-diethylcarbamoyl)piperidino)decane
-
N,N'-bis(1-decylnipecotoyl)piperazine